Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers develop blood test that can detect genetic changes in progressive breast cancer

08.06.2004


Researchers at UT Southwestern Medical Center at Dallas have developed a blood test that can detect amplification of a certain gene found in circulating cells associated with breast cancer.



If further clinical studies bear out its effectiveness, researchers say the blood test could be used as a standard operating procedure to monitor genetic changes for which a treatment is available.

"Cancer is a moving target, and the oncologist has to know which bullet to put in his gun," said Dr. Jonathan Uhr, professor of microbiology and internal medicine in the Cancer Immunobiology Center at UT Southwestern and senior author of the study. "Obtaining repeated blood samples is a safe and routine procedure, and this test can help the oncologist determine whether a new genetic change has become dominant and calls for a specific treatment for that change."


Their work will appear in an upcoming issue of the Proceedings of the National Academy of Sciences and is currently available online.

The researchers developed a blood test to optimize the detection and characterization of circulating cancer cells shed from a primary tumor. This is done by matching the cells’ genetic abnormalities with the parent tumor.

The test can detect one circulating tumor cell in 10 million white blood cells, said Dr. Uhr.

The research augments previous work by UT Southwestern researchers to determine if patients whose primary tumor did not have amplification of the gene HER-2 could acquire amplification if the tumor recurred and progressed. Using the new blood test to examine the circulating tumor cells from growing tumors, initial indications are this amplification eventually can occur, Dr. Uhr said.

Dr. Uhr says that in a patient whose primary tumor is classified as HER-2 gene non-amplified, a minute number of tumor cells actually may be HER-2 amplified. With time and selective pressures, this small population expands and becomes the predominant one.

Overexpression of the HER-2 gene occurs in about 20 percent to 25 percent of breast-cancer patients. Prognosis is poor, as the cancer cells often resist radiation therapy and almost all drugs.

However, studies have shown that the drug Herceptin (an antibody to HER-2) can treat tumors with HER-2 amplification by itself in 25 percent of patients and in 50 percent when combined with chemotherapy. The antibody binds to the molecules that are produced by the HER-2 gene and reside on the cancer cells’ surface. The drug neutralizes their effect with far fewer side effects than conventional chemotherapy.

By utilizing this blood test to determine HER-2 gene amplification in circulating cancer cells, doctors may be able to provide Herceptin to certain patients who have acquired such amplification. At present, HER-2 amplification is only diagnosed in the primary tumor.

"The implications of tumor evolution over the course of treatment are significant," said Dr. Debasish Tripathy, professor of internal medicine and contributing author. "A better understanding of this process will not only allow us to use available drugs in a more individualized fashion but also may point to new therapeutic approaches." Dr. Tripathy heads the Komen/UT Southwestern Breast Cancer Research Program.

The next step is to evaluate patients whose circulating tumor cells have acquired HER-2 gene amplification to determine if these cells are reflecting the genetic status of the recurrent tumor, said Dr. Uhr. For the blood test to be considered worthwhile, research also must show that therapy with Herceptin alone or in addition to a chemotherapeutic agent can cause remissions in a significant number of patients.


Other UT Southwestern contributors to the PNAS study were Dr. Raheela Ashfaq, professor of pathology; Dr. Eugene Frenkel, professor of internal medicine; Dr. Marilyn Leitch, professor of surgical oncology; Dr. David Euhus, associate professor of surgical oncology; Dr. Barbara Haley, associate professor of internal medicine; Dr. Cynthia Osborne, assistant professor of internal medicine; Dr. Susan Hoover, assistant professor of surgical oncology; Dr. Edward Clifford, clinical assistant professor of surgery; and in the Cancer Immunobiology Center, Dr. Ellen Vitetta, director; Dr. Songdong Meng, postdoctoral researcher; Dr. Jianqiang Wang, postdoctoral researcher; Thomas Tucker, senior research scientist; and Nancy Lane, research scientist.

Researchers from UT M.D. Anderson Cancer Center; Texas Oncology PA; Dallas Surgical Group; Cancer Center Associates in Dallas; Vysis, Inc.; Wistar Institute; Immunicon Corp.; the Washington University School of Medicine in St. Louis; and Germany’s University of Tubingen also contributed.

Research was supported by the Raymond D. Nasher Cancer Research Program and the Komen/UT Southwestern Breast Cancer Research Program.

To automatically receive news releases from UT Southwestern via e-mail, subscribe at http://www.utsouthwestern.edu/utsw/cda/dept37326/files/37813.html

Scott Maier | EurekAlert!
Further information:
http://www.utsouthwestern.edu/utsw/cda/dept37326/files/37813.html

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>